Gilead taps Nurix pro­tein de­grad­er op­tion for $20M

Four years af­ter first en­ter­ing a col­lab­o­ra­tion with Nurix, Gilead is pony­ing up an op­tion ex­er­cise pay­ment of $20 mil­lion to li­cense tar­get­ed pro­tein de­grad­er GS-6791.

It’s the first can­di­date to come from the agree­ment, with the po­ten­tial for $425 mil­lion in mile­stone pay­ments and low dou­ble-dig­it tiered roy­al­ties on prod­uct net sales.

GS-6791 is an oral IRAK4 de­grad­er that tar­gets in­flam­ma­to­ry re­spons­es. De­grad­ing IRAK4 could lead to po­ten­tial treat­ments in rheuma­toid arthri­tis and oth­er in­flam­ma­to­ry dis­eases, ac­cord­ing to a press re­lease.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN